AbbVie Inc (ABBV) : Capstone Asset Management Co scooped up 5,485 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 210,684 shares of AbbVie Inc which is valued at $13,144,575.AbbVie Inc makes up approximately 0.38% of Capstone Asset Management Co’s portfolio.
Other Hedge Funds, Including , Atria Investments boosted its stake in ABBV in the latest quarter, The investment management firm added 6,959 additional shares and now holds a total of 55,723 shares of AbbVie Inc which is valued at $3,476,558. AbbVie Inc makes up approx 0.32% of Atria Investments’s portfolio.Raymond James Trust N.a. boosted its stake in ABBV in the latest quarter, The investment management firm added 6,772 additional shares and now holds a total of 142,401 shares of AbbVie Inc which is valued at $9,015,407. AbbVie Inc makes up approx 0.78% of Raymond James Trust N.a.’s portfolio.Carroll Financial Associates boosted its stake in ABBV in the latest quarter, The investment management firm added 247 additional shares and now holds a total of 4,158 shares of AbbVie Inc which is valued at $263,243. AbbVie Inc makes up approx 0.04% of Carroll Financial Associates’s portfolio.Franklin Street Advisors Inc Nc boosted its stake in ABBV in the latest quarter, The investment management firm added 2,666 additional shares and now holds a total of 164,178 shares of AbbVie Inc which is valued at $10,407,243. AbbVie Inc makes up approx 1.91% of Franklin Street Advisors Inc Nc’s portfolio.Eqis Capital Management reduced its stake in ABBV by selling 3,219 shares or 25.4% in the most recent quarter. The Hedge Fund company now holds 9,452 shares of ABBV which is valued at $599,162. AbbVie Inc makes up approx 0.04% of Eqis Capital Management’s portfolio.
AbbVie Inc closed down -0.92 points or -1.45% at $62.39 with 53,08,425 shares getting traded on Tuesday. Post opening the session at $63.08, the shares hit an intraday low of $62.05 and an intraday high of $63.26 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by JP Morgan to ” Neutral” on Sep 8, 2016. Raymond James Initiated AbbVie Inc on Sep 2, 2016 to “Outperform”, Price Target of the shares are set at $82.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.